Table 1 A summery of clinical, neuropathological and oncological characteristics of the patients with long-term epilepsy-associated tumors, who underwent transcriptional analysis.
From: Long-term epilepsy-associated tumors: transcriptional signatures reflect clinical course
N | Sex | Age at surgery (years) | Last available outcome (Engel) | Neuro- pathological examination | Associated FCD | Hippocampus sclerosis | WHO | CD 34 | IDH mutation | MIB | Dead | Recurrence | Transcriptional signature |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 42 | Ia | DNT | no | no | I | negative | WT | 2–5% | no | no | 1 |
2 | M | 28 | Ia | DNT | no | no | I | positive | WT | 1% | no | no | 1 |
3 | M | 10 | IIIa | DNT | no | no | I | positive | WT | 5% | no | yes | 1 |
4 | M | 48 | Ia | DNT | no | no | I | negative | WT | NA | no | no | 1 |
5 | M | 70 | Ia | DNT | no | no | I | NA | WT | <1% | no | no | 1 |
6 | M | 15 | Ia | DNT | no | no | I | negative | WT | <1% | no | no | 1 |
7 | M | 12 | Ia | DNT | no | no | I | positive | WT | <1% | no | no | 1 |
8 | M | 14 | Ia | PXA | no | no | II | positive | WT | 11–20% | no | yes | 2 |
9 | M | 25 | Ia | GG | no | no | I | negative | WT | 2–5% | no | yes | 2 |
10 | F | 27 | Ia | GG | no | no | I | positive | WT | 2–5% | no | no | 2 |
11 | F | 16 | Ia | GG | no | no | I | positive | WT | <1% | no | no | 2 |
12 | M | 27 | Ia | GG | no | no | I | positive | WT | <1% | no | no | 2 |
13 | F | 20 | IIIa | PXA | no | no | III | negative | WT | 20% | no | yes | 2 |
14 | M | 16 | Ia | DNT | no | no | I | negative | WT | 2–5% | no | no | 4 |
15 | M | 41 | Ia | GG | no | no | I | negative | WT | 1% | no | no | 4 |
16 | F | 33 | Ia | GG | no | no | I | positive | WT | <1% | no | no | 4 |
17 | M | 20 | Ia | DNT | no | no | I | positive | WT | <1% | no | no | 4 |
18 | M | 17 | Ia | DNT | no | no | I | positive | WT | <1% | no | no | 4 |
